Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.

The most common side effects include allergic reactions, which include infusion related reactions, injection site reactions, brief pain, weakness and others.

Casirivimab/imdevimab

The combination is approved under the brand name Ronapreve for medical use in Japan, the United Kingdom, the European Union, and Australia.

Casirivimab/imdevimab

In January 2022, the U.S. Food and Drug Administration (FDA) revised the authorizations for two monoclonal antibody treatments – bamlanivimab/etesevimab (administered together) and casirivimab/imdevimab – to limit their use to only when the recipients are likely to have been infected with or exposed to a variant that is susceptible to these treatments because data show these treatments are highly unlikely to be active against the omicron variant.

Casirivimab/imdevimab

Medical uses

In the European Union, the combination is indicated for the treatment of COVID19 in people aged twelve years of age and older weighing at least who do not require supplemental oxygen and who are at high increased risk of progressing to severe COVID19; and for the prevention of COVID19 in people aged twelve years of age and older weighing at least .

Deployment

REGEN‑COV is manufactured at the Regeneron's manufacturing facility in Rensselaer, New York. In September 2020, to free up manufacturing capacity for REGEN‑COV, Regeneron began to shift production of its existing products from Rensselaer to the Irish city of Limerick.

Regeneron has a deal in place with Roche (Genentech) to manufacture and market REGEN‑COV outside the United States.

Society and culture

On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. The drug was provided by the company in response to a "compassionate use" (temporary authorization for use) request from the president's physicians.

In August 2021, Texas Governor Greg Abbott received REGEN‑COV after testing positive for COVID19.

Economics

In January 2021, the United States agreed to purchase 1.25 million doses of the drug for $2.625 billion, at $2,100 per dose. On 14 September, another 1.4 million doses were purchased for the same price, totaling $2.94 billion.

In January 2021, the German government purchased 200,000 doses for €400 million at €2,000 per dose.

In May 2021, Roche India and Cipla announced that the medicine would be available in India for Rs 59,750 ($) per dose.

In September 2021, the World Health Organization urged producers and governments to address the drug's high cost and called for technology sharing to enable the manufacture of biosimilar versions. The WHO also said that Unitaid is negotiating with Roche for lower prices and equitable distribution, especially in low- and middle income countries.

Legal status

In November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for casirivimab/imdevimab (Ronapreve) for the treatment and prevention of COVID19. The company that applied for authorization of Ronapreve is Roche Registration GmbH. Casirivimab/imdevimab was approved for medical use in the European Union in November 2021.

Research

COVID-19

On 21 November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate [COVID19] in people twelve years of age or older weighing at least with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID19. This includes those who are 65 years of age or older or who have certain chronic medical conditions. Casirivimab and imdevimab must be administered together by intravenous (IV) infusion or subcutaneous injection.